Keros Therapeutics, Inc.KROSNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank86
3Y CAGR+14.4%
5Y CAGR+30.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+14.4%/yr
vs +78.4%/yr prior
5Y CAGR
+30.1%/yr
Recent deceleration
Acceleration
-64.0pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
3.7x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $171.93M | -19.8% |
| 2024 | $214.38M | +26.0% |
| 2023 | $170.09M | +48.2% |
| 2022 | $114.79M | +50.1% |
| 2021 | $76.47M | +66.1% |
| 2020 | $46.05M | +130.2% |
| 2019 | $20.00M | +76.7% |
| 2018 | $11.32M | - |